Exosomes: a double-edged sword in cancer immunotherapy

Abstract

Over the past few decades, immunotherapy has emerged as a powerful strategy to overcome the limitations of conventional cancer treatments. The use of extracellular vesicles, particularly exosomes, which carry cargoes capable of modulating the immune response, has been extensively explored as a potential therapeutic approach in cancer immunotherapy. Exosomes can deliver their cargo to target cells, thereby influencing their phenotype and immunomodulatory functions. They exhibit either immunosuppressive or immune-activating characteristics, depending on their internal contents. These exosomes originate from diverse cell sources, and their internal contents can vary, suggesting that there may be a delicate balance between immune suppression and stimulation when utilizing them for immunotherapy. Therefore, a thorough understanding of the molecular mechanisms underlying the role of exosomes in cancer progression is essential. This review focuses on the molecular mechanisms driving exosome function and their impact on the tumor microenvironment (TME), highlighting the intricate balance between immune suppression and activation that must be navigated in exosome-based therapies. Additionally, it underscores the challenges and ongoing efforts to optimize exosome-based immunotherapies, thereby making a significant contribution to the advancement of cancer immunotherapy research.

Keywords

exosome / immune stimulatory / immune suppressive / tumor

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023; 21(11): 1142-1147.

[3] Netsirisawan P, Chokchaichamnankit D, Saharat K, Srisomsap C, Svasti J, Champattanachai V. Quantitative proteomic analysis of the association between decreasing O-GlcNAcylation and metastasis in MCF-7 breast cancer cells. Int J Oncol. 2020; 56(6): 1387-1404.

[4] de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3): 374-403.

[5] Inoue T, Adachi K, Kawana K, et al. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. Int J Oncol. 2016; 49(4): 1297-304.

[6] Wang S, Li Y, Xing C, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res. 2020; 10(7): 1937-1953.

[7] Struth E, Labaf M, Karimnia V, et al. Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging studies of 3D co-culture models. Sci Rep. 2024; 14(1): 20698.

[8] Goyette MA, Stevens LE, DePinho CR, et al. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proc Natl Acad Sci USA. 2024; 121(20): e2322688121.

[9] Zhang P, Wang Q, Lu W, Zhang F, Wu D, Sun J. NNT-AS1 in CAFs-derived exosomes promotes progression and glucose metabolism through miR-889-3p/HIF-1α in pancreatic adenocarcinoma. Sci Rep. 2024; 14(1): 6979.

[10] Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018; 15(10): 617-638.

[11] Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019; 30(1): 36-50.

[12] Chen Y, Liu X, Yuan H, et al. Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery. Adv Sci (Weinh). 2019; 6(5): 1802070.

[13] von Roemeling CA, Wang Y, Qie Y, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020; 11(1): 1508.

[14] Lu Y, Huntoon K, Lee D, et al. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nat Nanotechnol. 2022; 17(12): 1332-1341.

[15] Agudo J, Miao Y. Stemness in solid malignancies: coping with immune attack. Nat Rev Cancer. 2024; 25(1): 27-40.

[16] Dong S, Liu X, Bi Y, et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat Commun. 2023; 14(1): 6610.

[17] Wang Y, Deng W, Lee D, et al. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nat Nanotechnol. 2024; 19(2): 255-263.

[18] Huang Y, Liu K, Li Q, Yao Y, Wang Y. Exosomes function in tumor immune microenvironment. Adv Exp Med Biol. 2018; 1056: 109-122.

[19] Wu Y, Han W, Dong H, Liu X, Su X. The rising roles of exosomes in the tumor microenvironment reprogramming and cancer immunotherapy. MedComm. 2024; 5(4): e541.

[20] Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023; 23(4): 236-250.

[21] Huang Y, Arab T, Russell AE, et al. Toward a human brain extracellular vesicle atlas: characteristics of extracellular vesicles from different brain regions, including small RNA and protein profiles. Interdiscip Med. 2023; 1(4): e20230016.

[22] Zhang H, Wang S, Sun M, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2022; 13: 1093607.

[23] Zhu Q, Zhang Y, Li M, et al. MiR-124-3p impedes the metastasis of non-small cell lung cancer via extracellular exosome transport and intracellular PI3K/AKT signaling. Biomark Res. 2023; 11(1): 1.

[24] Shi J, Zhang H, Cui Y, et al. Extracellular vesicles for breast cancer diagnosis and therapy. Extracellular Vesicle. 2024; 3: 100039.

[25] Sun M, Zhang H, Liu J, et al. Extracellular vesicles: a new star for gene drug delivery. Int J Nanomedicine. 2024; 19: 2241-2264.

[26] Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019; 88: 487-514.

[27] Nkwe DO, Pelchen-Matthews A, Burden JJ, Collinson LM, Marsh M. The intracellular plasma membrane-connected compartment in the assembly of HIV-1 in human macrophages. BMC Biol. 2016; 14: 50.

[28] Booth AM, Fang Y, Fallon JK, Yang JM, Hildreth JE, Gould SJ. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J Cell Biol. 2006; 172(6): 923-35.

[29] Han QF, Li WJ, Hu KS, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022; 21(1): 207.

[30] Ma Y, Dong S, Li X, Kim BYS, Yang Z, Jiang W. Extracellular vesicles: an emerging nanoplatform for cancer therapy. Front Oncol. 2020; 10: 606906.

[31] Yang X, Ma Y, Xie H, et al. Extracellular vesicles in the treatment of parkinson’s disease: a review. Curr Med Chem. 2021; 28(31): 6375-6394.

[32] Magoling BJA, Wu AY, Chen YJ, et al. Membrane protein modification modulates big and small extracellular vesicle biodistribution and tumorigenic potential in breast cancers in vivo. Adv Mater. 2023; 35: e2208966.

[33] Squadrito ML, Cianciaruso C, Hansen SK, De Palma M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods. 2018; 15(3): 183-186.

[34] Gastpar R, Gehrmann M, Bausero MA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005; 65(12): 5238-47.

[35] Budnik V, Ruiz-Cañada C, Wendler F. Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci. 2016; 17(3): 160-72.

[36] Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4: 27066.

[37] He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018; 8(1): 237-255.

[38] Morey A, Ng M, Spanos M, et al. The EV antibody database: an interactive database of curated antibodies for extracellular vesicle and nanoparticle research. Extracell Vesicle. 2024; 3: 100040.

[39] Chen Z, Qiao Z, Wirth CR, Park HR, Lu Q. Arrestin domain-containing protein 1-mediated microvesicles (ARMMs) protect against cadmium-induced neurotoxicity. Extracell Vesicle. 2023; 2: 100027.

[40] Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010; 78(9): 838-48.

[41] Kugeratski FG, Kalluri R. Exosomes as mediators of immune regulation and immunotherapy in cancer. Febs J. 2021; 288(1): 10-35.

[42] Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3): 195-208.

[43] Tkach M, Kowal J, Théry C. Why the need and how to approach the functional diversity of extracellular vesicles. Philos Trans R Soc Lond B Biol Sci. 2018; 373(1737): 20160479.

[44] Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120(2): 457-71.

[45] Chen J, Sun W, Zhang H, et al. Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1β. Cell Mol Immunol. 2020; 17(12): 1233-1244.

[46] Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017; 77(23): 6480-6488.

[47] Huang Y, Kanada M, Ye J, et al. Exosome-mediated remodeling of the tumor microenvironment: from local to distant intercellular communication. Cancer Lett. 2022; 543: 215796.

[48] Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020; 6(13): eaay9789.

[49] Zhou Y, Ye T, Ye C, et al. Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy. Bioact Mater. 2022; 9: 541-553.

[50] Lu L, Zi H, Zhou J, et al. Engineered microparticles for treatment of murine brain metastasis by reprograming tumor microenvironment and inhibiting MAPK pathway. Adv Sci (Weinh). 2023; 10: e2206212.

[51] Zhang Q, Yang X, Liu H. Extracellular vesicles in cancer metabolism: implications for cancer diagnosis and treatment. Technol Cancer Res Treat. 2021; 20: 15330338211037821.

[52] Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174: 63-78.

[53] Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021; 11(7): 3183-3195.

[54] György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015; 55: 439-464.

[55] Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016; 164: 1226-1232.

[56] Yang J, Li Y, Jiang SP, et al. Engineered brain-targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma. Exploration. 2024;20240039.

[57] Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018; 560(7718): 382-386.

[58] Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019; 177(2): 414-427. e13.

[59] Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015; 17(6): 816-26.

[60] Xu Y, Leng K, Yao Y, et al. A circular RNA, cholangiocarcinoma-associated circular RNA 1, contributes to cholangiocarcinoma progression, induces angiogenesis, and disrupts vascular endothelial barriers. Hepatology. 2021; 73(4): 1419-1435.

[61] Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. Directional cell movement through tissues is controlled by exosome secretion. Nat Commun. 2015; 6: 7164.

[62] Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019; 1871(2): 455-468.

[63] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017; 20(2): 185-204.

[64] Deng C, Zhao J, Zhou S, et al. The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors. Mol Ther. 2020; 28(1): 75-88.

[65] Dal-Bianco JP, Aikawa E, Bischoff J, et al. Myocardial infarction alters adaptation of the tethered mitral valve. J Am Coll Cardiol. 2016; 67(3): 275-87.

[66] Zhang T, Zhou J, Man GCW, et al. MDSCs drive the process of endometriosis by enhancing angiogenesis and are a new potential therapeutic target. Eur J Immunol. 2018; 48(6): 1059-1073.

[67] Zimta AA, Baru O, Badea M, Buduru SD, Berindan-Neagoe I. The role of angiogenesis and pro-angiogenic exosomes in regenerative dentistry. Int J Mol Sci. 2019; 20(2): 406.

[68] Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2(10): 795-803.

[69] Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9(6): 669-76.

[70] Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016; 30(5): 668-681.

[71] Tang MKS, Yue PYK, Ip PP, et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat Commun. 2018; 9(1): 2270.

[72] Yi H, Ye J, Yang XM, Zhang LW, Zhang ZG, Chen YP. High-grade ovarian cancer secreting effective exosomes in tumor angiogenesis. Int J Clin Exp Pathol. 2015; 8(5): 5062-70.

[73] Millimaggi D, Mari M, D’Ascenzo S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007; 9(4): 349-57.

[74] LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol. 2016; 18(4): 356-65.

[75] Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat. 2004; 7(4-5): 289-300.

[76] Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglìo SR, Baldini N. Exosomes: novel effectors of human platelet lysate activity. Eur Cell Mater. 2014; 28: 137-51; discussion 151.

[77] Ekström EJ, Bergenfelz C, von Bülow V, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer. 2014; 13: 88.

[78] Feng W, Dean DC, Hornicek FJ, Shi H, Duan Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer. 2019; 18(1): 124.

[79] Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019; 19(1): 9-31.

[80] Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2): 139-46.

[81] Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011; 71(11): 3792-801.

[82] Li G, Yi X, Du S, et al. Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition. Oncogene. 2023; 42(6): 421-433.

[83] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527(7578): 329-35.

[84] Alonso-Alconada L, de la Fuente A, Santacana M, et al. Biomimetic device and foreign body reaction cooperate for efficient tumour cell capture in murine advanced ovarian cancer. Dis Model Mech. 2020; 13(6): dmm043653.

[85] Dezutter-Dambuyant C, Durand I, Alberti L, et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. Oncoimmunology. 2016; 5(3): e1091146.

[86] Fu R, Zhang YW, Li HM, et al. LW106, a novel indoleamine 2, 3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. Br J Pharmacol. 2018; 175(14): 3034-3049.

[87] Zhao Y, Shen M, Wu L, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023; 14(9): 587.

[88] Arina A, Idel C, Hyjek EM, et al. Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci USA. 2016; 113(27): 7551-6.

[89] Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021; 18(12): 792-804.

[90] Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021; 20(1): 131.

[91] Dou D, Ren X, Han M, et al. Cancer-associated fibroblasts-derived exosomes suppress immune cell function in breast cancer via the miR-92/PD-L1 pathway. Front Immunol. 2020; 11: 2026.

[92] Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019; 18(1): 91.

[93] Ringuette Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through tgfβ signaling. Mol Cancer Res. 2018; 16(7): 1196-1204.

[94] Fang T, Lv H, Lv G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018; 9(1): 191.

[95] Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018; 37(1): 324.

[96] Cho JA, Park H, Lim EH, et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol. 2011; 123(2): 379-86.

[97] Mo Y, Leung LL, Mak CSL, et al. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer. 2023; 22(1): 4.

[98] Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer. 2015; 34(12): 541-53.

[99] Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020; 368(6487): eaaw5473.

[100] Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016; 16(10): 619-34.

[101] Yang L, Achreja A, Yeung TL, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 2016; 24(5): 685-700.

[102] Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009; 8(23): 3984-4001.

[103] Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012; 11(6): 1108-17.

[104] Qu S, Xue H, Dong X, et al. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018; 143(2): 419-429.

[105] Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020; 5(1): 242.

[106] Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017; 16(1): 76.

[107] Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020; 2(2): 132-141.

[108] Song L, Liu Z, Hu HH, et al. Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun. 2020; 11(1): 5842.

[109] Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013; 52(4): 585-9.

[110] Yu L, Wang C, Zhang D, et al. Exosomal circ_0008285 in follicle fluid regulates the lipid metabolism through the miR-4644/LDLR axis in polycystic ovary syndrome. J Ovarian Res. 2023; 16(1): 113.

[111] Zhan Y, Qiao W, Yi B, et al. Dual role of pseudogene TMEM198B in promoting lipid metabolism and immune escape of glioma cells. Oncogene. 2022; 41(40): 4512-4523.

[112] Zhang C, Wang XY, Zhang P, et al. Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. Cell Death Dis. 2022; 13(1): 57.

[113] Arrieta VA, Cacho-Díaz B, Zhao J, Rabadan R, Chen L, Sonabend AM. The possibility of cancer immune editing in gliomas. A critical review. Oncoimmunology. 2018; 7(7): e1445458.

[114] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331(6024): 1565-70.

[115] Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019; 51(8): 1-13.

[116] Zhou C, Wei W, Ma J, et al. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021; 29(4): 1512-1528.

[117] Chen SW, Zhu SQ, Pei X, et al. Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol Cancer. 2021; 20(1): 144.

[118] Wen SW, Sceneay J, Lima LG, et al. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. Cancer Res. 2016; 76(23): 6816-6827.

[119] He YM, Li X, Perego M, et al. Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. Nat Med. 2018; 24(2): 224-231.

[120] Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019; 12(1): 84.

[121] Wang J, De Veirman K, De Beule N, et al. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. 2015; 6(41): 43992-4004.

[122] Fabbri M. Natural killer cell-derived vesicular miRNAs: a new anticancer approach? Cancer Res. 2020; 80(1): 17-22.

[123] Yu Y, Li T, Ou M, et al. OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy. J Control Release. 2024; 365: 469-479.

[124] Jiang H, Zhou L, Shen N, et al. M1 macrophage-derived exosomes and their key molecule lncRNA HOTTIP suppress head and neck squamous cell carcinoma progression by upregulating the TLR5/NF-κB pathway. Cell Death Dis. 2022; 13(2): 183.

[125] Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278: 121137.

[126] Su MJ, Aldawsari H, Amiji M. Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems. Sci Rep. 2016; 6: 30110.

[127] Moradi-Chaleshtori M, Bandehpour M, Soudi S, Mohammadi-Yeganeh S, Hashemi SM. In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes. Cancer Immunol Immunother. 2021; 70(5): 1323-1339.

[128] Moradi-Chaleshtori M, Shojaei S, Mohammadi-Yeganeh S, Hashemi SM. Transfer of miRNA in tumor-derived exosomes suppresses breast tumor cell invasion and migration by inducing M1 polarization in macrophages. Life Sci. 2021; 282: 119800.

[129] Zhen X, Li Y, Yuan W, et al. Biointerface-engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment. Adv Mater. 2024:e2401495.

[130] Guo J, Zhao W, Xiao X, et al. Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer. Bioact Mater. 2024; 39: 206-223.

[131] Anguille S, Smits EL, Bryant C, et al. Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev. 2015; 67(4): 731-53.

[132] Wang Y, Xiang Y, Xin VW, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020; 13(1): 107.

[133] Lu Z, Zuo B, Jing R, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017; 67(4): 739-748.

[134] Liu Y, Gu Y, Cao X. The exosomes in tumor immunity. Oncoimmunology. 2015; 4(9): e1027472.

[135] Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015; 8: 83.

[136] Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol. 2002; 14(7): 713-22.

[137] Montecalvo A, Shufesky WJ, Stolz DB, et al. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol. 2008; 180(5): 3081-90.

[138] Lindenbergh MFS, Stoorvogel W. Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu Rev Immunol. 2018; 36: 435-459.

[139] Pitt JM, André F, Amigorena S, et al. Dendritic cell-derived exosomes for cancer therapy. J Clin Invest. 2016; 126(4): 1224-32.

[140] Clayton A, Court J, Navabi H, et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods. 2001; 247(1-2): 163-74.

[141] Théry C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999; 147(3): 599-610.

[142] Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol. 2002; 3(12): 1156-62.

[143] Nakayama M. Antigen presentation by MHC-dressed cells. Front Immunol. 2014; 5: 672.

[144] Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol. 2006; 18(3): 363-70.

[145] Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183(3): 1161-72.

[146] Giri PK, Schorey JS. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS One. 2008; 3(6): e2461.

[147] Neviani P, Wise PM, Murtadha M, et al. Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res. 2019; 79(6): 1151-1164.

[148] Lugini L, Cecchetti S, Huber V, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2012; 189(6): 2833-42.

[149] Zhu L, Kalimuthu S, Gangadaran P, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017; 7(10): 2732-2745.

[150] Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018; 23(2): 181-192. e5.

[151] Tao B, Du R, Zhang X, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release. 2023; 363: 692-706.

[152] Greening DW, Gopal SK, Xu R, Simpson RJ, Chen W. Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol. 2015; 40: 72-81.

[153] He X, Ma Y, Xie H, et al. Biomimetic nanostructure platform for cancer diagnosis based on tumor biomarkers. Front Bioeng Biotechnol. 2021; 9: 687664.

[154] Wang X, Zhi X, Yang Z, et al. A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT). Oncotarget. 2017; 8(28): 45345-45355.

[155] Wang X, Yang Z, Tian H, et al. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget. 2017; 8(15): 24892-24901.

[156] Lin S, Xiong W, Liu H, Pei L, Yi H, Guan Y. Profiling and integrated analysis of differentially expressed circular RNAs in plasma exosomes as novel biomarkers for advanced-stage lung adenocarcinoma. Onco Targets Ther. 2020; 13: 12965-12977.

[157] Wang X, Kwak KJ, Yang Z, et al. Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One. 2018; 13(6): e0198552.

[158] Durrani-Kolarik S, Pool CA, Gray A, et al. miR-29b supplementation decreases expression of matrix proteins and improves alveolarization in mice exposed to maternal inflammation and neonatal hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2017; 313(2): L339-L349.

[159] Lee LJ, Yang Z, Rahman M, et al. Extracellular mRNA detected by tethered lipoplex nanoparticle biochip for lung adenocarcinoma detection. Am J Respir Crit Care Med. 2016; 193(12): 1431-3.

[160] Xu C, Jiang C, Li Z, et al. Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases. MedComm. 2024; 5(8): e660.

[161] Peng XX, Yu R, Wu X, et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. J Immunother Cancer. 2020; 8(1):e000376corr1.

[162] Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020; 20(4): 209-215.

[163] Zeng X, Wu C, Xiong Y, et al. Target proteins-regulated DNA nanomachine-electroactive substance complexes enable separation-free electrochemical detection of clinical exosome. Biosens Bioelectron. 2024; 256: 116273.

[164] Zocco D, Bernardi S, Novelli M, et al. Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. Sci Rep. 2020; 10(1): 15745.

[165] LeBleu VS, Kalluri R. Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. 2020; 6(9): 767-774.

[166] Nie W, Wu G, Zhang J, et al. Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angew Chem Int Ed Engl. 2020; 59(5): 2018-2022.

[167] Koh E, Lee EJ, Nam GH, et al. Exosome-SIRPα a CD47 blockade increases cancer cell phagocytosis. Biomaterials. 2017; 121: 121-129.

[168] Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021; 20(1): 154.

[169] Ye F, Wang Y, He Q, et al. Exosomes transmit viral genetic information and immune signals may cause immunosuppression and immune tolerance in ALV-J infected HD11 cells. Int J Biol Sci. 2020; 16(6): 904-920.

[170] Markov O, Oshchepkova A, Mironova N. Immunotherapy based on dendritic cell-targeted/-derived extracellular vesicles—a novel strategy for enhancement of the anti-tumor immune response. Front Pharmacol. 2019; 10: 1152.

[171] Zuo B, Zhang Y, Zhao K, et al. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol. 2022; 15(1): 46.

[172] Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Control Release. 2023; 353: 423-433.

[173] Huang L, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022; 21(1): 45.

[174] Xu J, Liao K, Zhou W. Exosomes regulate the transformation of cancer cells in cancer stem cell homeostasis. Stem Cells Int. 2018; 2018: 4837370.

[175] Abudoureyimu M, Zhou H, Zhi Y, et al. Recent progress in the emerging role of exosome in hepatocellular carcinoma. Cell Prolif. 2019; 52(2): e12541.

[176] Sun L, Zhu W, Zhao P, et al. Down-regulated exosomal microRNA-221-3p derived from senescent mesenchymal stem cells impairs heart repair. Front Cell Dev Biol. 2020; 8: 263.

[177] Liu M, Hu Y, Chen G. The antitumor effect of gene-engineered exosomes in the treatment of brain metastasis of breast cancer. Front Oncol. 2020; 10: 1453.

[178] Wang B, Yao K, Huuskes BM, et al. Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis. Mol Ther. 2016; 24(7): 1290-301.

[179] Liu X, Li Q, Niu X, et al. Exosomes secreted from human-induced pluripotent stem cell-derived mesenchymal stem cells prevent osteonecrosis of the femoral head by promoting angiogenesis. Int J Biol Sci. 2017; 13(2): 232-244.

[180] Zhao B, Li X, Shi X, et al. Exosomal microRNAs derived from human amniotic epithelial cells accelerate wound healing by promoting the proliferation and migration of fibroblasts. Stem Cells Int. 2018; 2018: 5420463.

[181] Zhao S, Liu Y, Pu Z. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro. Drug Des Devel Ther. 2019; 13: 2887-2897.

[182] Zhang C, Gan X, Liang R, Jian J. Exosomes derived from epigallocatechin gallate-treated cardiomyocytes attenuated acute myocardial infarction by modulating microRNA-30a. Front Pharmacol. 2020; 11: 126.

[183] Yue Y, Wang C, Benedict C, et al. Interleukin-10 deficiency alters endothelial progenitor cell-derived exosome reparative effect on myocardial repair via integrin-linked kinase enrichment. Circ Res. 2020; 126(3): 315-329.

[184] Jiang Y, Xie H, Tu W, et al. Exosomes secreted by HUVECs attenuate hypoxia/reoxygenation-induced apoptosis in neural cells by suppressing miR-21-3p. Am J Transl Res. 2018; 10(11): 3529-3541.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.